ACHE and early-onset autosomal dominant Alzheimer disease: Like other AChE inhibitors, HupA has been most commonly evaluated in patients with Alzheimer’s disease (Yang et al., 2013; Qian and Ke, 2014) with specific focus on its ability to improve cognition (Rafii et al., 2011; Xu et al., 2012).